查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1412279

學名藥市場：按類型、給藥途徑、適應症、分佈分類 - 全球預測 2024-2030

Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Distribution - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年學名藥市場規模為2,991.6億美元，預計2024年將達3,162.7億美元，2030年將達4,474.5億美元，複合年成長率為5.91%。

全球學名藥市場

主要市場統計
基準年[2023] 2991.6億美元
預測年份 [2024] 3162.7億美元
預測年份 [2030] 4474.5億美元
複合年成長率（%） 5.91%
學名藥市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估學名藥市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對學名藥市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-學名藥市場的市場規模和預測是多少？

2-在學名藥市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-學名藥市場的技術趨勢和法律規範是什麼？

4-學名藥市場主要廠商的市場佔有率是多少？

5-進入學名藥市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和對具成本效益藥物的需求
      • 政府對學名藥的有利核准
      • 擴大網路藥局學名藥的可得性
    • 抑制因素
      • 病人和醫生對品牌藥物的偏好
    • 機會
      • 正在進行的與學名藥相關的研究和開發活動
      • 專利到期延長和學名藥生產策略長期合作夥伴關係
    • 任務
      • 對品質和製造差異的擔憂
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章學名藥市場：按類型

  • 簡單非專利
  • 專門食品非專利

第7章學名藥市場：依給藥途徑

  • 吸入式
  • 可注射的
  • 口服

第8章學名藥市場（按適應症）

  • 癌症
  • 心血管疾病
  • 中樞神經系統疾病
  • 糖尿病
  • 消化系統疾病
  • 荷爾蒙與相關疾病
  • 感染疾病
  • 呼吸系統疾病

第9章學名藥市場分佈

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲學名藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區學名藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲學名藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第14章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • Aspen Holdings
    • Aurobindo Pharma
    • Baxter International Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • Endo International plc.
    • Fresenius SE & Co. KGaA.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Hikma Pharmaceuticals PLC.
    • Johnson & Johnson Services, Inc.
    • Lupin
    • Mylan Laboratories Limited
    • Pfizer Inc.
    • Sandoz International GmbH by Novartis Group
    • Sanofi
    • STADA Arzneimittel AG
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceuticals Industries Ltd.
  • 主要產品系列

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-F6513A06BEC0

[195 Pages Report] The Generic Drugs Market size was estimated at USD 299.16 billion in 2023 and expected to reach USD 316.27 billion in 2024, at a CAGR 5.91% to reach USD 447.45 billion by 2030.

Global Generic Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 299.16 billion
Estimated Year [2024] USD 316.27 billion
Forecast Year [2030] USD 447.45 billion
CAGR (%) 5.91%
Generic Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Generic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Generic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aspen Holdings, Aurobindo Pharma, Baxter International Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin, Mylan Laboratories Limited, Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi, STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Simple Generic
    • Specialty Generic
  • Route of Administration
    • Inhalable
    • Injectable
    • Oral
  • Indication
    • Cancer
    • Cardiovascular Diseases
    • Central Nervous System Disorders
    • Diabetes
    • Gastrointestinal Diseases
    • Hormones & Related Diseases
    • Infectious Diseases
    • Respiratory Diseases
  • Distribution
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Generic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Generic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Generic Drugs Market?

4. What is the market share of the leading vendors in the Generic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Generic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Generic Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Favorable government approvals for generic drugs
      • 5.1.1.3. Growing availability of generic drugs through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic drugs
      • 5.1.3.2. Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Generic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Simple Generic
  • 6.3. Specialty Generic

7. Generic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalable
  • 7.3. Injectable
  • 7.4. Oral

8. Generic Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Diseases
  • 8.4. Central Nervous System Disorders
  • 8.5. Diabetes
  • 8.6. Gastrointestinal Diseases
  • 8.7. Hormones & Related Diseases
  • 8.8. Infectious Diseases
  • 8.9. Respiratory Diseases

9. Generic Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Generic Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Aspen Holdings
    • 14.1.3. Aurobindo Pharma
    • 14.1.4. Baxter International Inc.
    • 14.1.5. Dr. Reddy's Laboratories Ltd.
    • 14.1.6. Eli Lilly and Company
    • 14.1.7. Endo International plc.
    • 14.1.8. Fresenius SE & Co. KGaA.
    • 14.1.9. Gilead Sciences, Inc.
    • 14.1.10. GlaxoSmithKline PLC
    • 14.1.11. Glenmark Pharmaceuticals Ltd.
    • 14.1.12. Hikma Pharmaceuticals PLC.
    • 14.1.13. Johnson & Johnson Services, Inc.
    • 14.1.14. Lupin
    • 14.1.15. Mylan Laboratories Limited
    • 14.1.16. Pfizer Inc.
    • 14.1.17. Sandoz International GmbH by Novartis Group
    • 14.1.18. Sanofi
    • 14.1.19. STADA Arzneimittel AG
    • 14.1.20. Sun Pharmaceutical Industries Ltd.
    • 14.1.21. Teva Pharmaceuticals Industries Ltd.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENERIC DRUGS MARKET DYNAMICS
  • FIGURE 7. GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC DRUGS MARKET SIZE, BY SIMPLE GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GENERIC DRUGS MARKET SIZE, BY SPECIALTY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 9. GENERIC DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GENERIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GENERIC DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GENERIC DRUGS MARKET SIZE, BY HORMONES & RELATED DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GENERIC DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 22. GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 193. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 194. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. GENERIC DRUGS MARKET LICENSE & PRICING